RT @ChristieLibrary: New @CochraneBCancer Review - Risk-reducing medications for primary #breastcancer - https://t.co/bnZcr7lCuu
RT @clinicallibrar1: Risk‐reducing medications for primary breast cancer: a network meta‐analysis - Mocellin, S - 2019 | Cochrane Library h…
RT @clinicallibrar1: Risk‐reducing medications for primary breast cancer: a network meta‐analysis - Mocellin, S - 2019 | Cochrane Library h…
Risk‐reducing medications for primary breast cancer: a network meta‐analysis - Mocellin, S - 2019 | Cochrane Library https://t.co/bunN7CO9nU
RT @Actual_clinica: Medicinas para prevenir el cáncer de mama en las mujeres con riesgo por encima de la media de desarrollar cáncer de mam…
Medicinas para prevenir el cáncer de mama en las mujeres con riesgo por encima de la media de desarrollar cáncer de mama Cochrane https://t.co/3SDA63OI5D
[#Cochrane] Médicaments pour prévenir le cancer du sein chez les femmes présentant un risque supérieur à la moyenne de développer un cancer du sein : https://t.co/w9TSTO71sI
"Médicaments pour prévenir le cancer du sein chez les femmes présentant un risque supérieur à la moyenne de développer un cancer du sein | Cochrane": https://t.co/YP5Xry5SMd
Médicaments pour prévenir le cancer du sein chez les femmes présentant un risque supérieur à la moyenne de développer un cancer du sein https://t.co/j5Zp4pVTPM
#Médicaments pour #prévenir le #cancer_du_sein chez les femmes présentant un risque supérieur à la moyenne de développer un cancer du sein : https://t.co/9rGLnTwkl6
RT @ChristieLibrary: New @CochraneBCancer Review - Risk-reducing medications for primary #breastcancer - https://t.co/bnZcr7lCuu
RT @SBoolbol: Risk reducing medications. Know your options #breastcancer #riskreducing #options https://t.co/HBSdMko0I7
Risk reducing medications. Know your options #breastcancer #riskreducing #options
RT @ChristieLibrary: New @CochraneBCancer Review - Risk-reducing medications for primary #breastcancer - https://t.co/bnZcr7lCuu
New @CochraneBCancer Review - Risk-reducing medications for primary #breastcancer - https://t.co/bnZcr7lCuu
プラセボと比較してタモキシフェン(TAM)、アロマターゼ阻害薬(AI)は乳癌発症のリスクを低下させる。AIはTAMより効果的かもしれない。TAMは子宮体癌と血栓塞栓症のリスクを増加させるがAIはリスク増加と関連しない。ラロキシフェンはTAMより効果は悪いが、毒性も低い。 https://t.co/YNEuXVVdxG
RT @cochrane_nz: New Cochrane Review - Risk-reducing medications for primary #breastcancer- https://t.co/73xiSDfPtD 6 studies with 50,927 w…
RT @cochrane_nz: New Cochrane Review - Risk-reducing medications for primary #breastcancer- https://t.co/73xiSDfPtD 6 studies with 50,927 w…
New Cochrane Review - Risk-reducing medications for primary #breastcancer- https://t.co/73xiSDfPtD 6 studies with 50,927 women. Current evidence supports the use of cancer prevention agents such as selective estrogen receptor modulators and aromatase inhib
RT @CochraneLibrary: New @CochraneBCancer Review - Risk-reducing medications for primary #breastcancer - https://t.co/NOidQ4HrhV 6 studies…
RT @CochraneLibrary: New @CochraneBCancer Review - Risk-reducing medications for primary #breastcancer - https://t.co/NOidQ4HrhV 6 studies…
New @CochraneBCancer Review - Risk-reducing medications for primary #breastcancer - https://t.co/NOidQ4HrhV 6 studies enrolling 50,927 women. Specialized method, network meta‐analysis, allowed comparison of medications never directly compared to each other
RT @CochraneLibrary: New @CochraneBCancer Review - Risk-reducing medications for primary breast cancer https://t.co/NOidQ4HrhV 6 studies en…
New @CochraneBCancer Review - Risk-reducing medications for primary breast cancer https://t.co/NOidQ4HrhV 6 studies enrolling 50,927 women. Specialized method, network meta‐analysis, allowed comparison of medications never directly compared to each other i
New review that assesses the efficacy and acceptability of risk-reducing medications for the prevention of primary breast cancer - https://t.co/cIet1gg95a
RT @CochraneLibrary: New @CochraneBCancer Review - Risk-reducing medications for primary breast cancer https://t.co/NOidQ4HrhV 6 studies en…
RT @CochraneLibrary: New @CochraneBCancer Review - Risk-reducing medications for primary breast cancer https://t.co/NOidQ4HrhV 6 studies en…
New @CochraneBCancer Review - Risk-reducing medications for primary breast cancer https://t.co/NOidQ4HrhV 6 studies enrolling 50,927 women. Specialized method, network meta‐analysis, allowed comparison of medications never directly compared to each other i